上海鼎新基因科技

Dingxin Gene is a clinical-stage biotechnology company headquartered in Shanghai, China, dedicated to the development of AAV-based gene therapies for rare and life-threatening diseases. The company's primary focus lies in ophthalmology and hematology, with a lead program, DXG-001, targeting RPE65-related inherited retinal dystrophies. Dingxin Gene leverages its proprietary vector engineering and optimization platform to enhance the safety and efficacy of its therapeutic candidates. Supported by leading life science investors, the company is advancing a diverse pipeline through clinical development and manufacturing scale-up. Its mission is to provide transformative treatments for patients with genetic disorders who currently have limited therapeutic options.